Conflict of Interest

The author has declared no conflict of interest.

Diagnosing and treating Acute HIV Infection (AHI) in a high HIV incidence setting: Eswatini










Background



* Laboratory Testing for the Diagnosis of HIV Infection: Centers for Disease Control and Prevention and Association of Public Health Laboratories.

- Acute HIV Infection (AHI) is characterised by high levels of plasma HIV RNA with non-specific clinical presentations.
- It cannot be diagnosed by routinely available pointulletof-care antibody tests.
- AHI enhances the risk of HIV transmission, lacksquarespecifically in high HIV incidence settings like Eswatini.
- Improving detection of AHI and rapid antiretroviral ullettherapy (ART) initiation could contribute to HIV elimination goals.











Methodology

- Objective: Assess the burden of AHI and feasibility of diagnosing and treating AHI in a resource limited setting
- Study setting: Outpatient department (OPD) in Nhlangano secondary health facility
- Study eligibility: Adults 16 49 years old AND
- HIV rapid diagnostic test (RDT: Determine Unigold) negative AND symptoms suggestive of AHI (fever/ sore throat/ symptoms of sexually transmitted infection)
- OR inconclusive HIV RDT
- OR referred from the PrEP and PEP (pre- and post-exposure prophylaxis) programme
- **Diagnosis:** Quantitative HIV RNA detection by Gene Xpert platform:
- Definition of AHI: One viral load (VL) >10,000 copies/mL or 2 VLs >40 copies/mL



Overview of AHI cascade





Characteristics of patients

		No AHI (n=585)	AHI (n=26)	P Value /%
Age	Median (IQR)	26.6 (23.5 - 30.9)	26.7 (24.2 - 29.7)	
	Male	254	5	0.045
Gender	Female	331	21	0.015
	No Partner	31	0	0.912
Number of Doute or (c)	One Partner	362	17	
Number of Partner(s)	Two Partners	107	6	
	Three/more Partners	68	3	
	Fever	261	9	0.311
	Sorethroat	211	9	0.875
	Headache	219	8	0.487
	General fatigue	98	7	0.180
Presenting complaints	Lower abdominal pain	130	7	0.577
	Genital itchiness	163	6	0.590
	Red eye and itchiness of eyes	59	5	0.137
	General body pain/ache	78	4	0.768
	General body pain/ache78Swollen glands23	23	4	0.023
Clinical Observations Genital ulcers Pharyngitis	Genital discharge	153	9	0.342
	Genital ulcers	65	3	1.000
	Oral ulcer	6	3	0.005
	Pharyngitis	26	3	0.120
	Temp >37.5'C	56	3	0.731
	Immediate		12	75%
ART initiation	Within one week		4	25%



Characteristics of patients

		No AHI (n=585)	AHI (n=26)	P Value /%	
Age	Median (IQR)	26.6 (23.5 - 30.9)	26.7 (24.2 - 29.7)		
	Male	254	5	0.045	
Gender	Female	331	21	0.015	
Number of Partner(s)	No Partner	31	0		
	One Partner	362	17	0.912	
	Two Partners	107	6		
	Three/more Partners	68	3	-	
	Fever	261	9	0.311	
	Sorethroat	211	9	0.875	
	Headache	219	8	0.487	
	General fatigue	98	7	0.180	
Presenting complaints	Lower abdominal pain	130	7	0.577	
	Genital itchiness	163	6	0.590	
	Red eye and itchiness of eyes	59	5	0.137	
	General body pain/ache	78	4	0.768	
	Swollen glands	211 219 219 98 98 130 163 99	4	0.023	
Clinical Observations	Genital discharge	153	9	0.342	
	Genital ulcers	65	3	1.000	
	Oral ulcer	6	3	0.005	
	Pharyngitis	26	3	0.120	
	Temp >37.5'C	5'C 56 3	0.731		
ADT initiation	Immediate		12	75%	
ART initiation	Within one week	56 3	4	25%	




Characteristics of patients

		No AHI (n=585)	AHI (n=26)	P Value /%	
Age	Median (IQR)	26.6 (23.5 - 30.9)	26.7 (24.2 - 29.7)		
	Male	254	5	0.045	
Gender	Female	331	21	0.015	
	No Partner	31	0		
Number of Dortoor(o)	One Partner	362	17		
Number of Partner(s)	Two Partners	107	6	- 0.912	
	Three/more Partners	68	3		
	Fever	261	9	0.311	
	Sorethroat	211	9	0.875	
	Headache	219	8	0.487	
	General fatigue	98	7	0.180	
Presenting complaints	Lower abdominal pain	130	7	0.577	
	Genital itchiness	163	6	0.590	
	Red eye and itchiness of eyes	59	5	0.137	
	General body pain/ache	78	4	0.768	
	Swollen glands	98 130 130 163 eyes 59 78 23 153 65	4	0.023	
Clinical Observations	Genital discharge	153	9	0.342	
	Genital ulcers	65	3	1.000	
	Oral ulcer	6	3	0.005	
	Pharyngitis	26	3	0.120	
	Temp >37.5'C 5		3	0.731	
ADT initiation	Immediate		12	75%	
ART initiation	Within one week		4	25%	




Changes in median viral RNA (VL log₁₀)






Changes in median viral RNA (VL log₁₀)



	n	Min	Median	Max
n	16	3.1	5.08	7
<	11	undetectable	2.16	5.39
h	10	undetectable	1.66	3.54
h	9	undetectable	undetectable	3.7
h	6	undetectable	undetectable	2.22
h	5	undetectable	undetectable	2.66
h	4	undetectable	undetectable	1.95
h	3	undetectable	undetectable	undetectable




Changes in median CD4 count






Changes in median CD4 count



Duration since ART initiation



Changes in median CD4 count



Duration since ART initiation











20 partners notified

6 HIV RDT +






20 partners notified

6 HIV RDT +


Refer to initiate ART








































- Diagnosing and treating Acute HIV Infection (AHI) in a routine public ulletsector OPD setting is feasible
- Rapid viral suppression was observed soon after ART initiation
- ART initiation is required to optimise for health benefit of patients and reduction of forward transmission (due to high VLs)
- Partner/contact tracing and rapid linkage to care are major challenges in the situation of recent infection

Conclusion



Acknowledgement

Thanks to the patients, healthcare workers of Nhlangano health centre, and MSF team.

Aung Aung ¹, Charlie Mamba ¹, Nombuso Ntshalintshali ¹, Qhubekani Mpala ¹, Simangele Mthethwa-Hleza ², Dumile Sibandze ³, Gugu Maphalala ³, Lenhle Dube ², Rufaro Kashangura ⁴, Marie Luce Tombo ¹, Roberto de la Tour ⁵, Alex Telnov ⁵, Barbara Rusch ⁵, Alan Gonzalez ⁵, Iza Ciglenecki ⁵, Bernhard Kerschberger ¹

- 1. Medecins Sans Frontieres, Nhlangano, Eswatini, Eswatini
- 2. National AIDS Program, MoH, Mbabane, Eswatini,
- 3. National Reference Laboratory, MoH, Mbabane, Eswatini,
- 4. Nhlangano Health Center, MoH, Nhlangano, Eswatini,
- 5. Medecins Sans Frontieres, Geneva, Switzerland

The study received ethics approval from MSF Ethics Review Board and Eswatini National Health Research Review Board.

















